Vnitr Lek 2013, 59(2):120-126

Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidlines related to the diagnostics and treatment of dyslipidemias issued in 2011

V. Soška1,2, H. Vaverková3, M. Vrablík4,*, V. Bláha5, R. Cífková6, T. Freiberger7, P. Kraml8, J. Piťha9, H. Rosolová10, T. Štulc4, Z. Urbanová11
1 Oddělení klinické biochemie, Mezinárodní centrum klinického výzkumu a FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Soška, CSc.
2 II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
3 III. interní klinika - nefrologická, revmatologická a endokrinologická Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Josef Zadražil, CSc.
4 III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
5 III. interní gerontometabolická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
6 Centrum kardiovaskulární prevence 1. lékařské fakulty UK a Thomayerovy nemocnice Praha, vedoucí centra prof. MUDr. Renata Cífková, CSc.
7 Centrum kardiovaskulární a transplantační chirurgie Brno, ředitel doc. MUDr. Petr Němec, CSc., MBA, FETCS
8 II. interní klinika 3. lékařské fakulty UK a FN Královské Vinohrady Praha, přednosta prof. MUDr. Michal Anděl, CSc.
9 Laboratoř pro výzkum aterosklerózy IKEM Praha, vedoucí MUDr. Jan Piťha, CSc.
10 II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc.
11 Klinika dětského a dorostového lékařství 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Jiří Zeman, DrSc.

This position statement of the Executive Committee of the Czech Society for Atherosclerosis (CSAT) summarizes the most important aspects and novelties of the latest European guidelines for the management of dyslipidemia. In particular the position statement comments on: cardiovascular risk stratification, indications for plasma lipid and lipoprotein levels assessment as well as target lipid values, evaluation of current options for both lifestyle and pharmacological treatment of lipid metabolism disorders and, also, recommendation for laboratory monitoring of patients treated with lipid lowering agents. The statement deals with actual concepts of management of dyslipiemia in everyday practice, e.g. therapy of dyslipidemia in special patients' groups. This statement does not replace the latest guidelines but focuses on the changes from the former guidelines for dyslipidemia management, published by CSAT in 2007.

Keywords: dyslipidemia; risk stratification; LDL-cholesterol; statins; fibrates; niacin; ezetimibe; resins

Received: January 22, 2013; Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V, Vaverková H, Vrablík M, Bláha V, Cífková R, Freiberger T, et al.. Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidlines related to the diagnostics and treatment of dyslipidemias issued in 2011. Vnitr Lek. 2013;59(2):120-126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Catapano AL, Reiner Z, Backer GD et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Aterosclerosis Society (EAS). Aterosclerosis 2011; 217: 3-46. Go to original source... Go to PubMed...
    2. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197. Go to PubMed...
    3. Perk J, Backer GD, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol 2012; 19: 585-667.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.